Genetic evidence for repurposing GLP‐1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti‐inflammatory pathways beyond glycaemic control
This study provides robust genetic evidence for repurposing GLP-1RAs in CKD and IgAN through anti-inflammatory (FGF23) and metabolic pathways, extending their utility beyond glucose control. While European ancestry data limit generalisability, our framework prioritises FGF23 and metabolic modulation as key targets for clinical trials in renal protection.
Authors
- Xueying Yang (ORCID: https://orcid.org/0000-0002-1209-4943)
- Wenhao Tang (ORCID: https://orcid.org/0000-0002-4063-0846)
- Mo Wang (ORCID: https://orcid.org/0000-0001-7004-3549)
- Haiping Yang (ORCID: https://orcid.org/0000-0002-0456-9304)
- Qiu Li (ORCID: https://orcid.org/0000-0002-2481-7168)
- Han Chan
Institutions
- Tân Tạo University (VN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1111/dom.70144
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29